2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions

View by Date

Monday, September 23, 2019

1:45pm-3:15pm: Botulinum toxin type A therapy in a movement disorders unit: a 23-year experience.

M. Velez, C. Cosentino, L. Torres (Lima, Peru)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: BouNDless: An active-controlled randomized, double-blind double-dummy study of continuous ND0612 infusion in patients with fluctuating Parkinson’s disease

W. Poewe, K. Kieburtz, F. Stocchi, S. Oren, T. Yardeni, L. Adar, O. Rosenfeld, C. Olanow (Innsbruck, Austria)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Brain and spinal cord structural alterations in non-ataxic and ataxic SCA3 mutation carriers

J. Faber, I. Giordano, B. Koyak, R. Wolz, S. Romanzetti, MC. Franca Jr, H. Jiang, A. Durr, B. Bender, J. Diedrichsen, T. Klockgether (Bonn, Germany)

Ataxia · Les Muses, Level 3

1:45pm-3:15pm: Brain MRI Volume Changes after 12 months laquinimod treatment of Huntington disease (LEGATO-HD)

R. Reilmann, M. Gordon, A. Feigin, K. Anderson, S. Tabrizi, B. Leavitt, J. Stout, P. Piccini, N. Hobbs, R. Manber, B. Borowsky, G. Rynkowski, R. Volkinshtein, J. Savola, M. Hayden (Victoria, Australia)

Huntington’s Disease · Agora 3 West, Level 3

1:45pm-3:15pm: Brain MRI-based discrimination between multiple system atrophy type cerebellar from other late onset sporadic cerebellar ataxias: a prospective study with implications for diagnosis criteria

G. Carré, JL. Dietemann, O. Gebus, S. Montaut, O. Lagha-Boukbiza, T. Wirth, S. Kremer, IJ. Namer, M. Anheim, C. Tranchant (Strasbourg, France)

Ataxia · Les Muses, Level 3

1:45pm-3:15pm: Burden of Huntington’s disease in the US: Analysis of an insured population

K. Raimundo, J. Luo, R. Tan, T. To, R. Fuller, J. Warner (South San Francisco, CA, USA)

Huntington’s Disease · Agora 3 West, Level 3

1:45pm-3:15pm: Can a smartphone accelerometer differentiate between functional and organic tremor ?

M. Khider Ahmed, T. Mouton, J. Ackerman, N. Brey, C. Albertyn, F. Henning, J. Carr (Cape Town, South Africa)

Functional (Psychogenic) Movement Disorders · Les Muses Terrace, Level 3

1:45pm-3:15pm: Can people with Parkinson’s disease rely on their coping capacity over time? A longitudinal study using the Sense of Coherence (SOC) scale

J. Andersson, G-M. Hariz, L. Forsgren (Umeå, Sweden)

Other · Agora 2 West, Level 2

1:45pm-3:15pm: Can we hear pathology in premanifest Huntington’s disease? Acoustic and listener-based analysis of speech

J. Chan, C. Shirbin, J. Stout, A. Vogel (Melbourne, Australia)

Huntington’s Disease · Agora 3 West, Level 3

1:45pm-3:15pm: Cardiac involvement in AVED

S. Lucas-Delpozo, D. Moreno-Martínez, M. Tejero-Ambrosio, J. Hernández-Vara (Barcelona, Spain)

Ataxia · Les Muses, Level 3